Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
91.6 EUR | -1.59% | +3.05% | +2.01% |
08:05am | Sanofi: new positive data for Beyfortus | CF |
04-30 | Sanofi Announces Board and Committee Appointments | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.01% | 124B | B+ | ||
+32.95% | 699B | C+ | ||
+26.24% | 571B | B | ||
-3.14% | 364B | C+ | ||
+18.32% | 326B | B- | ||
+4.23% | 286B | C+ | ||
+14.74% | 236B | B+ | ||
+4.55% | 198B | B- | ||
-11.12% | 194B | A+ | ||
-4.72% | 154B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SAN Stock
- Ratings Sanofi